TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, non-randomized, open-label, Phase I/II clinical trial of MDG1011, an
investigational medicinal product (IMP), consisting of patient-derived autologous T cells,
persistently transduced with a Preferentially Expressed Antigen in Melanoma (PRAME)-specific
human leukocyte antigen (HLA)-A*02:01-restricted T cell receptor (TCR).